Diabetes Type 2

Regional Health is involved in diabetes research trials. Below is more information about the purpose and who the physician (principal investigator) is for each trial. For more in-depth information on the research studies, click the blue name which will lead you to the U.S. National Institute of Health website.


EXSCEL:Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus.

PURPOSE: This study will compare the impact of including exenatide once weekly in addition to usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary composite endpoint of cardiovascular-related death, nonfatal myocardial infarction (MI), or nonfatal stroke.

To learn more, contact:
Black Hills
Cardiovascular Research

4150 5th Street
Rapid City, SD

(605) 755-4326

Principal Investigator
L Norman Ferrier, MD FACC
Cardiologist

THEMIS:A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

PURPOSE: The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.

To learn more, contact:
Black Hills
Cardiovascular Research

4150 5th Street
Rapid City, SD

(605) 755-4326

Principal Investigator
Michael D'Urso, MD FACC
Cardiologist

Novo Ellipse: Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes (Ellipse™)

PURPOSE: The aim of this trial is to assess the efficacy and safety of liraglutide in the paediatric population in order to potentially address the unmet need for treatment of children and adolescents with type 2 diabetes.

To learn more, contact:
Regional Health
Clinical Research

Email: Research

(605) 755-3982

Principal Investigator
Rachel Edelen, MD
Pediatric Endocrinologist

ELIXA: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome

PURPOSE:
Primary Objective:
To demonstrate that lixisenatide can reduce cardiovascular morbidity and mortality [composite endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina] compared to placebo in type 2 diabetic patients who recently experienced an acute coronary syndrome (ACS) event.
Secondary Objectives:
To demonstrate that when compared to placebo, lixisenatide can reduce composite endpoint of cardiovascular death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina, or hospitalization for heart failure composite endpoint of cardiovascular death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina, hospitalization for heart failure, or coronary revascularization procedure urinary albumin excretion (based on the urinary albumin/creatinine ratio). To assess the safety and tolerability of lixisenatide.

To learn more, contact:
Black Hills
Cardiovascular Research

4150 5th Street
Rapid City, SD

(605) 718-2610

Principal Investigator
Alex M.A. Schabauer, MD FSVMB FACC
Cardiologist